A strength of our study was the ability to exclude BIRC5 from the PAM50 algorithm (the research version of the Prosigna assay) to independently assess BIRC5/survivin as a high-risk biomarker in breast cancer and its relationship with tumor subtype. This evidence concerns the gene BIRC5 and neoplasm.